Newer Pharmacologic Treatments in Adults With Type 2 Diabetes
Summary of Recommendations
- Use an SGLT-2 inhibitor to reduce the risk for all-cause mortality, major adverse cardiovascular events, progression of chronic kidney disease, and hospitalization due to congestive heart failure.
- Use a GLP-1 agonist to reduce the risk for all-cause mortality, major adverse cardiovascular events, and stroke.
Recommendation Grading
Disclaimer
Overview
Title
Newer Pharmacologic Treatments in Adults With Type 2 Diabetes
Authoring Organization
American College of Physicians
Publication Month/Year
April 19, 2024
Last Updated Month/Year
May 1, 2024
Supplemental Implementation Tools
Document Type
Guideline
Country of Publication
US
Document Objectives
The American College of Physicians (ACP) developed this clinical guideline to update recommendations on newer pharmacologic treatments of type 2 diabetes. This clinical guideline is based on the best available evidence for effectiveness, comparative benefits and harms, consideration of patients’ values and preferences, and costs.
Target Patient Population
Adults with type 2 diabetes
Target Provider Population
Internists, family practitioners, and other clinicians caring for patients with T2DM
Inclusion Criteria
Male, Female, Adult, Older adult
Health Care Settings
Ambulatory
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Treatment, Management
Diseases/Conditions (MeSH)
D003920 - Diabetes Mellitus, D003924 - Diabetes Mellitus, Type 2
Keywords
diabetes, diabetes mellitus, type 2 diabetes mellitus, Type 2 Diabetes , GLP-1, SGLT-2
Source Citation
Amir Qaseem, Adam J. Obley, Tatyana Shamliyan, et al; Clinical Guidelines Committee of the American College of Physicians. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians. Ann Intern Med. [Epub 19 April 2024]. doi:10.7326/M23-2788
Supplemental Methodology Resources
Systematic Review Document, Systematic Review Document, Data Supplement